Drug Trial Radar · NCT04648254
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Nov 18, 2020
Primary completion
Dec 23, 2025
Study completion Dec 23, 2025
Sponsor
- Lead sponsor
- Qurient Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered orally.
Conditions
- Solid Tumor
- Advanced Cancer
- Metastatic Cancer
Interventions
Q702Drug
The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD), the dose limiting toxicities (DLT) and the safety profile of Q702Time frame: 28 days of cycle 1
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Southern California
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Northwestern University
Chicago, Illinois
Atlantic Health System Hospital
Morristown, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.